New drug cocktail plus targeted procedure shows promise for tough liver cancers
NCT ID NCT03937830
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 24 times
Summary
This study tests whether combining three drugs (durvalumab, bevacizumab, tremelimumab) with a liver procedure called TACE can help people with advanced liver or bile duct cancer live longer without their cancer growing. About 27 adults with intermediate or advanced liver cancer or bile duct cancer will receive the drugs every 3 weeks and may have the TACE procedure multiple times. The main goal is to see how many participants are still cancer-free after 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.